Synchron Secures $200M Series D to Commercialize Brain-Computer Interface Platform
Key Insights
Synchron (search) raised $200 million in Series D funding to support commercialization of its Stentrode (search) brain (search)-computer interface system and prepare for pivotal trials.
The company's minimally invasive catheter-based approach offers 16 electrodes compared to Neuralink (search)'s 1,024, but enables severely paralyzed patients to control digital devices without open-brain (search) surgery.
Synchron (search) is developing a next-generation transcatheter high-channel whole-brain (search) interface while expanding operations to San Diego for vertically integrated manufacturing.
Synchron (search) has raised $200 million in Series D funding to advance commercialization of its brain (search)-computer interface platform, positioning the company to become the first to bring a BCI device to market while simultaneously developing next-generation technology. The round brings Synchron's total funding to $345 million and values the company at approximately $1 billion.
The funding will support preparations for the commercial launch of Synchron (search)'s first-generation Stentrode (search) BCI system, which translates brain (search) activity into digital commands without requiring open-brain surgery. Unlike competitors such as Neuralink (search), which requires removing part of the skull for implantation, Synchron's device is placed via a catheter procedure, offering a less invasive approach to brain-computer interfacing.
Technology Platform and Clinical Applications
Synchron (search)'s Stentrode (search) device features 16 electrodes compared to Neuralink (search)'s N1 Implant with 1,024 electrodes, representing a trade-off between procedural invasiveness and signal fidelity. Despite the lower electrode count, the device enables severely paralyzed patients to control personal devices hands-free. The FDA granted Synchron Breakthrough Designation for the Stentrode in 2020, and the company has been conducting an early feasibility study since 2022.
"This industry is going to unlock the brain (search)'s computational power in ways that are hard to imagine now. This is just the beginning," said Thomas Oxley, Synchron (search)'s founder and CEO, reflecting on the company's journey since its first human implant in 2019.
The company has published safety results and built applications with major technology partners including Apple (search), Amazon (search), OpenAI (search), and NVIDIA (search). In 2021, Synchron (search) achieved a milestone by enabling the world's first social media post from a BCI user named Philip on Twitter.
Next-Generation Development and Expansion
Approximately 20 percent of the Series D funding will support development of Synchron (search)'s next-generation system, described as a minimally invasive, transcatheter, high-channel count, whole-brain (search) interface. The company is establishing a new engineering hub in San Diego, led by industry veterans Andy Rasdal and Mark Brister, to build this advanced brain interface technology.
"It comes back to this idea that to be successful in BCI, you have to cover three things. One is access at scale, or getting out of the operating room. Two is coverage of the brain (search) without destroying the local architecture. And three is data, and using more data to generate better function," Oxley explained.
The San Diego facility will house a vertically integrated manufacturing operation, attracting talent from companies like Dexcom and Qualcomm. Meanwhile, Synchron (search) is expanding its AI team in New York City, training models to learn from brain (search) data with the goal of decoding thought in real time.
Investment Landscape and Market Position
The Series D round was led by Double Point Ventures (search), with participation from new investors including the Australian National Reconstruction Fund, T.Rx Capital, Qatar Investment Authority, K5 Global, Protocol Labs, and IQT. All existing investors, including ARCH Venture Partners (search), Khosla Ventures (search), and funds associated with Bill Gates and Jeff Bezos, participated in the round.
Synchron (search)'s funding contributes to a historic year for BCI investment, with total funding for implanted BCI companies in 2024 and 2025 exceeding $1 billion. This surge includes significant financings at Blackrock Neurotech (search), Neuralink (search), and Precision Neuroscience (search).
"I feel very lucky to have a range of investors who are taking a long term view on where this is going and supporting the journey," Oxley noted, emphasizing the significance of having all existing investors participate in the substantial fundraising round.
Competitive Landscape and Future Applications
Oxley described the current BCI field as experiencing a first wave focused on motor control, followed by speech applications, with vision emerging as a developing area. He anticipates significant growth in neural data availability, from tens of thousands of patient hours to hundreds and eventually millions of patient hours, which will drive better functionality for BCI users.
Regarding consumer applications, Oxley expressed optimism about Apple (search)'s potential to enable cognitive applications through AirPods but remained cautious about whole brain (search) implants for healthy individuals. "I think there's still going to be third or fourth generation systems before we get to that," he said, preferring applications that protect or restore cognitive decline (search) with age over "superhuman, transhumanist" narratives.
As Synchron (search) advances toward becoming the first company to achieve regulatory approval for a brain (search)-computer interface device, the substantial funding positions the company to execute both its near-term commercial strategy and long-term technological development goals in the rapidly evolving BCI market.